Difficulty: Medium
Average Score: 67%
Testbank
You are the nurse caring for a patient who is to receive IV daunorubicin, a chemotherapeutic agent. You start the infusion and check the insertion site as per protocol. During your most recent check, you note that the IV has infiltrated so you stop the infusion. What is your main concern with this infiltration?
Correct answer
A
Rationale
Extravasation of the medication is the main concern with this infiltration.
When IV daunorubicin infiltrates, there is a significant risk of extravasation, which can cause tissue damage and necrosis due to the cytotoxic nature of the drug. Prompt recognition and intervention are crucial to prevent severe complications that can arise from the infiltration of such a potent chemotherapeutic agent.
B: Discomfort to the patient may occur, but it is not the primary concern compared to the potential for severe tissue damage associated with extravasation of a chemotherapeutic agent like daunorubicin.
C: Blanching at the site can indicate compromised circulation, but it does not specifically address the critical issue of extravasation and its potential harm to surrounding tissues affected by the infiltrated medication.
D: Hypersensitivity reaction to the medication is a concern with any drug administration, but it is unrelated to the immediate risks associated with IV infiltration of daunorubicin and does not reflect the urgency of addressing potential extravasation.
When IV daunorubicin infiltrates, there is a significant risk of extravasation, which can cause tissue damage and necrosis due to the cytotoxic nature of the drug. Prompt recognition and intervention are crucial to prevent severe complications that can arise from the infiltration of such a potent chemotherapeutic agent.
B: Discomfort to the patient may occur, but it is not the primary concern compared to the potential for severe tissue damage associated with extravasation of a chemotherapeutic agent like daunorubicin.
C: Blanching at the site can indicate compromised circulation, but it does not specifically address the critical issue of extravasation and its potential harm to surrounding tissues affected by the infiltrated medication.
D: Hypersensitivity reaction to the medication is a concern with any drug administration, but it is unrelated to the immediate risks associated with IV infiltration of daunorubicin and does not reflect the urgency of addressing potential extravasation.